Biodel presents clinical trial results of VIAject at conference
DANBURY, Conn. A specialty biopharmaceutical company focused on endocrine disorder treatments will present results of two phase 3 studies for its investigational diabetes medication this week.
Biodel said its CEO, Sol Steiner, will unveil Friday results of two phase 2 studies of VIAject ultra-rapid-acting recombinant human insulin at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland. Recombinant human insulin is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs, Biodel said.
The company submitted VIAject to the Food and Drug Administration for market approval in late December.